Northwestern’s SuperAging Program studies the brains of older individuals with exceptional memories in order to better understand the science behind memory, aging and dementias such as Alzheimer’s disease.
Northwestern researchers discovered that an experimental drug called NU-9 shows promise as an early intervention for Alzheimer’s disease. Invented by chemistry professor Richard Silverman, NU-9 is a small molecule compound that is currently being tested as a treatment for ALS.
The brain works to consolidate memories during slumber. Researchers hope to amplify the effect, with possibilities for improving learning, creativity and recovery from injury.
Never miss a Northwestern Magazine story:
Get the latest stories from the magazine in your inbox six times per year.
Reader Responses
No one has commented on this page yet.
Submit a Response